• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Inaugural DNDi training for health & science journalists in Kampala

Home > News

Inaugural DNDi training for health & science journalists in Kampala

16 Oct 2018
Medical journalist Dr Mercy Korir
Medical journalist Dr Mercy Korir

In early October, 18 journalists from 11 African countries converged in Kampala, Uganda for DNDi’s first-ever training on health and science journalism. The three-day training was conducted on the sidelines of DNDi’s 11th Partners’ Meeting on 4 October 2018.

The objective of the health and science journalism workshop was to help reporters and editors better understand neglected diseases prevalent in the region and grasp the science behind efforts to develop new drugs for these diseases.

Mr Otula Owuor, a veteran Kenyan science journalist and trainer with the World Federation of Science Journalists, facilitated the training, which alternated presentations with interactive sessions. The journalists learned about neglected diseases directly from DNDi experts, including onchocerciasis (river blindness), mycetoma, human African trypanosomiasis (sleeping sickness), and leishmaniasis, and neglected patient populations such as children living with HIV. Dr Nathalie Strub-Wourgaft, Director of Neglected Tropical Diseases at DNDi, helped to “demystify” the clinical trials process with an in-depth talk on the ins and outs of drug development.

The journalists visited the Joint Clinical Research Centre in Lubowa, a clinical trial site for DNDi’s LIVING study, underway in Kenya and Uganda to demonstrate the effectiveness, safety, and acceptability of child-adapted HIV therapy, the so-called “2-in-1” pellets containing lopinavir and ritonavir (LPV/r), which are designed for infants and young children. The visit helped to improve the journalists’ understanding of what takes place during a clinical trial and gave them the opportunity to ask questions of Ugandan clinical trial experts.

Equipped with new skills and understanding, the journalists are already developing stories about neglected diseases and patients in their countries, and about related research and development activities.

A selection of articles published by participants of the workshop:

  • Al Jazeera Africa [27 March 2019] طبيبة كينية تعالج الناس بالصحافة “A Kenyan doctor treats people in the press”
  • New Business Ethiopia [9 February 2019] “Ethiopia makes progress against neglected tropical diseases”
  • The East African [1 November 2018] “New treatments offer hope for tropical diseases in Africa”
  • Habari RDC [24 October 2018] “Un nouveau medicament pour soigner la maladie du sommeil”
  • Politico DRC [14 October 2018] “Maladies tropicales négligées:les experts signalent des progrès dans l’éradication de la Trypanosomiase en RDC”
  • The Citizen [11 October 2018] “Children’s HIV drug formula developed”
  • Ghana Web [11 October 2018] “More resources needed to fight against neglected tropical diseases – Health experts”
  • Ghana Web [11 October 2018] “Pediatric HIV victims get attention”
  • Daily Monitor [10 October 2018] “HIV-positive children to take soluble ARVs”
  • The Star Tribune [8 October 2018] “Health organization celebrates 15 years fighting neglected diseases globally”
  • New Business Ethiopia [3 October 2018] “New clinical trials for neglected diseases in eastern Africa in progress”
  • Daily Nation [3 October 2018] “Children to get HIV drugs in powder form”
  • The Standard [3 October 2018] “Ray of hope for children with HIV and Aids”
Strengthening Capacities Paediatric HIV Africa Uganda

Read, watch, share

Loading...
Laboratory of Medicinal and Computational Chemistry (LQMC), São Paulo University USP, São Carlos Campus, São Paulo Brazil.
Press releases
13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security 

Chepokarial Rubben attentively cares for her five-year-old son, Romanu Kiptoo, at the kala-azar ward of Kacheliba Sub-County Referral Hospital in West Pokot County, Kenya. She gently soothes him, offering comfort as he endures the painful treatment for kala-azar.
Press releases
13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Press releases
8 Jul 2026

Brazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of India

Patricia, 44, from Area 44 in Lilongwe, Malawi, has lived with vision loss for 10 years following a late diagnosis of cryptococcal meningitis.
Stories
30 Jun 2026

Cryptococcal meningitis: Africa’s neglected HIV killer

News
29 Jun 2026

Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors 

Publications
29 Jun 2026

Advancing global health innovation through Europe-Africa collaboration

Mamadou Diop senior health technician - biologist at CERPAD Lab at Gaston Berger University
Stories
17 Jun 2026

The DNDi-MMV Joint Regulatory Platform: ‘a pioneering programme project for non-profit medical research organizations to speak with one voice’

MASAMUNA, DR CONGO, JANUARY 2026: The mother superior of the nuns who run the local clinic is also the lab technican.
Press releases
12 Jun 2026

DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license